Skyrizi ^*

Skyrizi (generic name: risankizumab-rzaa) is a humanized IgG1 monoclonal antibody that targets the p19 subunit of IL-23. This type of antibody helps calm down the immune system without completely shutting it off, making it a valuable option for people with chronic inflammatory diseases.

A Monoclonal Antibody is a lab-made protein that works like the body’s natural antibodies, which help fight off harmful invaders. But instead of attacking infections, this antibody is designed to target a specific part of the immune system:

IgG1 type refers to a specific class of antibody, known for being strong and long-lasting in the body. IL-23 (Interleukin-23) is a protein in the immune system that plays a key role in causing inflammation. It helps activate certain immune cells that can lead to conditions like psoriasis, Crohn’s disease, and other inflammatory disorders. The p19 subunit is a specific part of IL-23 that makes it active. By blocking the p19 subunit of IL-23, this antibody prevents IL-23 from triggering inflammation. This helps reduce symptoms in diseases that involve an overactive immune response. Skyrizi is commonly used for autoimmune diseases, where the immune system mistakenly attacks the body, including:

• Moderate to severe plaque psoriasis, where people may benefit from taking injections or pills (systemic therapy) or treatment using ultraviolet or UV light (phototherapy).
• Active psoriatic arthritis.
• Moderate to severe Crohn’s disease.
• Moderate to severe ulcerative colitis.

Clinical Benefits

Clinical trials have demonstrated that Skyrizi effectively reduces the severity of symptoms in patients with these conditions. In plaque psoriasis, patients achieved significant skin clearance, with many attaining a PASI 90 response, indicating a 90% reduction in the Psoriasis Area and Severity Index. For psoriatic arthritis, Skyrizi has been shown to improve joint symptoms and inhibit radiographic progression. In Crohn’s disease and ulcerative colitis, many patients experienced full clinical remission, with reductions in intestinal inflammation and improvements in quality of life.

Dosage

The dosing schedule varies depending on the specific condition and is set by the prescribing healthcare provider: Plaque psoriasis and psoriatic arthritis:

• Initial doses: 150 mg administered as a subcutaneous injection at Week 0 and Week 4.
• Maintenance dose: 150 mg every 12 weeks thereafter.

Crohn’s disease:

• Induction phase: 600 mg administered by intravenous infusion over at least one hour at Weeks 0, 4, and 8.
• Maintenance phase: 180 mg or 360 mg administered as a subcutaneous injection at Week 12, and then maintenance doses every 8 weeks thereafter.

Ulcerative colitis:

• Induction phase: 1,200 mg administered by intravenous infusion over at least two hours at Weeks 0, 4, and 8.
• Maintenance phase: 180 mg or 360 mg administered as a subcutaneous injection at Week 12, and then maintenance doses every 8 weeks thereafter.

It’s important to note that Skyrizi is available in different forms and strengths, including prefilled pens, cartridges, and vials, to accommodate the various dosing regimens. We supply only prefilled pens for self-administration. Patients may self-inject the subcutaneous doses after proper training and at the appropriate maintenance dose as determined by a healthcare provider based on individual patient needs. However, the intravenous infusions are usually administered only by a healthcare professional.

Storage

Skyrizi must be stored under refrigeration at 2°-8°C (36°-46°F) but not in the freezer. If in any doubt, consult our blog on safe medicine management.

Frequently Asked Questions About Skyrizi

What should I do if I miss a dose?

If a dose is missed, it’s important to contact a healthcare provider to determine the appropriate course of action.

Can Skyrizi be used during pregnancy or breastfeeding?

The effects of Skyrizi during pregnancy and breastfeeding are not well established. Women who are pregnant, planning to become pregnant, or breastfeeding should consult their healthcare provider before starting Skyrizi.

How does Skyrizi work?

Skyrizi is a humanized monoclonal antibody that targets the p19 subunit of interleukin-23 (IL-23), a protein involved in inflammatory processes. By inhibiting IL-23, Skyrizi helps reduce inflammation associated with certain autoimmune conditions.

Is Skyrizi a biologic medication?

Yes, Skyrizi is a biologic therapy. It is a monoclonal antibody designed to specifically target IL-23, a cytokine involved in inflammatory diseases. Unlike traditional immunosuppressants, biologics like Skyrizi offer targeted therapy with fewer systemic effects.

Is Skyrizi better than other psoriasis treatments?

Skyrizi has demonstrated higher skin clearance rates compared to some other biologics. In clinical trials, more than 80% of patients achieved PASI 90 (90% improvement in psoriasis symptoms) at 16 weeks, with 60% achieving complete skin clearance (PASI 100)

Are IL-23 inhibitors safer than TNF inhibitors?

IL-23 inhibitors like Skyrizi have a lower risk of serious infections compared to TNF inhibitors. However, they still carry some risks, including an increased risk of upper respiratory infections, tuberculosis, and hypersensitivity reactions.